Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient - 02/12/13
, Sarah Majercik, M.D., M.B.A., Joseph Bledsoe, M.D., Katie Smith, Pharm.D., Rob Johnston, Pharm.D., Justin Dickerson, Ph.D., M.B.A., Tom White, M.D.Abstract |
Background |
Limited data exist regarding the efficacy of weight-based dosing of low–molecular weight heparin for venous thromboembolism (VTE) prophylaxis in obese trauma patients.
Methods |
Consecutive obese trauma patients were placed on a weight-based protocol for VTE prophylaxis (enoxaparin .5 mg/kg subcutaneously every 12 hours). Peak anti-Xa levels were drawn, and bilateral lower extremity duplex ultrasound was performed. The incidence of VTE and bleeding complications were recorded.
Results |
Eighty-six patients met the study criteria. Seventy-four patients achieved target prophylactic anti-Xa concentrations, with a mean level of .42 ± .01 IU/mL. Eighteen patients were found to have deep vein thrombosis. However, in 16 of these patients, deep vein thrombosis was diagnosed before weight-based low–molecular weight heparin initiation. No bleeding complications occurred, and no symptomatic pulmonary emboli were identified.
Conclusions |
In obese trauma patients, weight-based enoxaparin is an efficacious regimen that provides adequate VTE prophylaxis, as measured by anti-Xa levels, and appears to be safe without bleeding complications.
El texto completo de este artículo está disponible en PDF.Keywords : Enoxaparin, Venous thromboembolism prophylaxis, VTE prophylaxis, Anti-Xa level, Obese, Trauma
Esquema
| The authors declare no conflicts of interest. |
Vol 206 - N° 6
P. 847-852 - décembre 2013 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
